Medindia

X

Sigma-Aldrich Announces Collaboration to Develop Monoclonal Antibodies

Friday, June 20, 2008 General News J E 4
Advertisement
ST. LOUIS, June 19 Sigma-Aldrich (Nasdaq: SIAL)today announced it has entered into a five-year collaboration to developoptimal cell lines for the production of monoclonal antibodies. Scientists atthe University of California, San Francisco will lead the research intoantibodies for a variety of cancer targets, autoimmune diseases, stem cellcharacteristics and commonly neglected disease targets.

Under the terms of the agreement, research targets will be determined by asteering committee composed of leading scientists at UCSF, including LewisLanier, Ph.D. Professor and Vice Chair, Department of Microbiology &Immunology; Jeffrey Bluestone, Ph.D. Director, UCSF Diabetes Center; and SusanFisher, Ph.D. Professor, Department of Cell & Tissue Biology. The committeewill direct research into antibodies for cancer targets, stem cell surfacemarkers and autoimmune disease targets. The University will have free accessto the antibodies resulting from the partnership for its ongoing immunologyand disease research.

"Sigma-Aldrich is committed to developing the most comprehensive andhighly validated collection of monoclonal antibodies available for the cellbiology research community," said Dr. David Smoller, President ofSigma-Aldrich's Research Biotech Business Unit. "By partnering with thehighly regarded UCSF research team, Sigma-Aldrich is helping to furtherpromote the study of a number of important cancer targets, regenerativemedicine applications and neglected diseases."

Sigma-Aldrich is expanding its antibody content offering as part of itsplan to become a leading developer and manufacturer of the next generation ofmonoclonal antibody products for life science researchers. Earlier this year,the company announced a partnership to distribute the highly-validatedPrestige antibodies powered by Atlas Antibodies, the commercial arm of theHuman Proteome Resource. Sigma-Aldrich is also collaborating with AbDSerotec, a Division of MorphoSys, to design, produce and distribute uniquerecombinant research antibodies using MorphoSys's proprietary HuCAL GOLDtechnology.

For more information on Sigma-Aldrich's extensive monoclonal antibodyproduct portfolio, visit the company's interactive Antibody Explorer catalogat http://www.sigmaaldrich.com/antibody.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and HighTechnology company. Our biochemical and organic chemical products and kitsare used in scientific and genomic research, biotechnology, pharmaceuticaldevelopment, the diagnosis of disease and as key components in pharmaceuticaland other high technology manufacturing. We have customers in life sciencecompanies, university and government institutions, hospitals, and in industry.Over one million scientists and technologists use our products. Sigma-Aldrichoperates in 36 countries and has 7,900 employees providing excellent serviceworldwide. Sigma-Aldrich is committed to Accelerating Customer Successthrough Leadership in Life Science, High Technology and Service. For moreinformation about Sigma-Aldrich, please visit our award-winning website athttp://www.sigma-aldrich.com.

About UCSF: UCSF is a leading university dedicated to promoting healthworldwide through advanced biomedical research, graduate-level education inthe life sciences and health professions, and excellence in patient care.

Cautionary Statement: This release contains forward-looking statementsrelating to future performance, goals, strategic actions and initiatives andsimilar intentions and beliefs and other statements regarding the Company'sexpectations, goals, beliefs, intentions and the like, which involveassumptions regarding the Company's operations and conditions in the marketsthe Company serves. The Company does not undertake any obligation to updatethese forward-looking statements.

UC Disclaimer: The information stated above was prepared
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Statement From Bayer(R) Aspirin Regarding the Amer...
S
Trubion Pharmaceuticals Announces Extension of Res...